TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04852484
Drug: local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before the operation, 19 mL of 0.5% Ropivacaine + 1 mL of normal saline (20 mL in total) will be injected in the paravertebral space. Afterwards, there will be a pump of 500 ml of 0.2 % ropivacaine connected to the catheter after the end of the surgery, administered continuously at a rate of 10 mL/hr
Study: NCT04524130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be given with the same rate of lidocaine or ketamine.
Study: NCT03962465
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal, administered on days 8 and 29
Study: NCT06333314
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: * mFOLFOX6 or FOLFIRI or XELOX regimen~* FOLFOX or XELOX or TFOX regimen~* FOLFIRINOX or gemcitabine-nab-paclitaxel or gemcitabine monotherapy.~* Cisplatin and gemcitabine cisplatin or CAPOX or mFOLFOX6.~* Etoposide-cisplatin-doxorubicin or mitotane~* Cisplatin and gemcitabine or carboplatin and paclitaxel~* Etoposide-cisplatin or etoposide-carboplatin~* Doxorubicin and ifosfamide or doxorubicin monotherapy or doxorubicin and trabectedin.
Study: NCT06047171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug product that will contain no active ingredient
Study: NCT06047171
Drug: Immunosuppressive Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressants are drugs that prevent your immune system from attacking healthy cells and tissues by mistake.
Study: NCT06200181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT05478525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule BID for 14 days (n=4)
Study: NCT05478525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo capsules BID for 14 days (n=4)
Study: NCT05478525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 placebo capsules BID for 14 days (n=4)
Study: NCT05034029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04921982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Placebo, 90 minutes prior to a brief memory reactivation session, performed by a trained nurse, once a week for six consecutive weeks.
Study: NCT06584188
Drug: anti-inflammatory ketorolac tromethamine
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Intra- radicular anti-inflammatory {ketorolac tromethamine at room temperature}.~* Intra- radicular cold anti-inflammatory {ketorolac tromethamine at 2-5C}.
Study: NCT05831189
Drug: RBX2660
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX2660 should be administered to the right side of the colon (i.e., between the ileocecal valve and the hepatic flexure of the colon).
Study: NCT00103831
Drug: Oral Taxane
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05607719
Drug: Bevespi
Normalized name: Bevespi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two puffs twice a day
Study: NCT05607719
Drug: Bretzri
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two puffs twice a day
Study: NCT06498349
Drug: best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.
Study: NCT05569759
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of placebo
Study: NCT05289167
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg IV over 1 hour on Day +3 and +4
Study: NCT05872620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT06297629
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06561919
Drug: best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment according to widely accepted consensus Paper
Study: NCT05667142
Drug: XEN1101
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN1101 capsules
Study: NCT05667142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT06103825
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo :QD，PO，Day 1-Day 84
Study: NCT05646563
Drug: NM8074
Approvals — FDA: no, EMA: no, PMDA: no
Description: NM8074 is an anti-Factor Bb humanized monoclonal antibody that will be administered as an intravenous infusion. Doses will be administered over a treatment period of 13 weeks.
Study: NCT05918055
Drug: KPT-8602
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-10 mg PO daily for 10-14 days based on dose level
Study: NCT06191965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills in identical appearance to the MitoQ capsules will be produced and provided by Antipodean Pharma and given to the patients in the control arm two per day to be taken one hour before breakfast. The composition of the placebo is tapioca starch, microcrystalline cellulose, hypromellose, silica-colloidal anhydrous, purified water, carrageenan, and pectin.
Study: NCT05895786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for PF-06823859
Study: NCT05531526
Drug: AR1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR1001 Active Oral Tablet
Study: NCT05531526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet
Study: NCT06009107
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously.
Study: NCT05423106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as an oral formulation.
Study: NCT06640972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05476094
Drug: Polyene Phosphatidylcholine
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
Study: NCT06393452
Drug: PP405 Topical Vehicle Gel
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: PP405 Vehicle = placebo
Study: NCT04732117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 150 mg s.c.at BSL, Weeks 1, 2 and 3, followed by administration every 4 weeks starting at Week 4.
Study: NCT06186037
Drug: Mono drug group of Rosuvastatin 20 mg
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral administration once a day, taking it for 3 years
Study: NCT05158244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily for 42 days
Study: NCT06340581
Drug: Treatment A: BGF MDI HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 4 oral inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
Study: NCT06340581
Drug: Treatment B: BGF MDI HFO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
Study: NCT06340581
Drug: Treatment C: BGF MDI HFO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose without spacer with charcoal.
Study: NCT05010707
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be prescribed the medication and dosed based on their hormonal profile. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Study: NCT05010707
Drug: Daily Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as once daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Study: NCT05010707
Drug: BID Sublingual Tablet
Normalized name: Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be prescribed the medication and dosed based on their hormonal profile. Participants will take dose as twice daily medication. Goal is achieve estradiol level between 100-200 pg/mL and to suppress testosterone to cisgender female levels
Study: NCT05010707
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will also receive spironolactone. Spironolactone will be started at 50 mg daily and will increase to standard dose.
Study: NCT06269133
Drug: REGN2810
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.
Study: NCT06598046
Drug: Utidelone and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Utidelone: intravenous capecitabine: oral
Study: NCT06438471
Drug: EC5026 oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be two ascending dose regimens of EC5026, which will be administered over two consecutive Treatment Periods. During each Treatment Period, EC5026 will be administered orally once daily for 7 consecutive days, with a loading dose on Day 1 and a maintenance dose on Days 2-7 of each treatment period. All study subjects will be enrolled in both Treatment Periods and will receive both dose regimens consecutively, for a total duration of 14 days.~Oral doses of EC5026 tested in each Treatment Period:~Treatment Period 1: 6 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 Treatment Period 2: 8 mg loading dose on Day 8 / 4 mg Maintenance dose on Days 9-14
Study: NCT06438471
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered a matching oral placebo for 14 consecutive days.
Study: NCT04733040
Drug: MOR202
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOR202 will be administered as an intravenous infusion
Study: NCT06530641
Drug: Custodiol Htk Soln
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing major cardiac surgery with extracorporeal circulation who are administered Custodiol crystalloid cardioplegia.
Study: NCT05097287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection subcutaneous
Study: NCT06705075
Drug: Perfluten
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of UCA Definity to evaluate uterine fibroids by contrast-enhanced ultrasound (CEUS) and subharmonic-aided pressure estimation (SHAPE) pre and post-uterine artery embolization (UAE).
Study: NCT05192889
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV), oral (PO), or Intrathecal (IT).
Study: NCT05192889
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given oral (PO).
Study: NCT05192889
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV).
Study: NCT05192889
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given oral (PO) or intravenously (IV).
Study: NCT05192889
Drug: Intrathecal Triples
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given Intrathecal (IT).
Study: NCT05177510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06018766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via dry powder inhaler
Study: NCT06056245
Drug: Intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of methadone 0.1mg/kg based on ideal body weight (up to a maximum dose of 20 mg), at the beginning of surgery.
Study: NCT06056245
Drug: Post-operative
Normalized name: POUCH,DRAINABLE,POST-OPERATIVE H#9760
Approvals — FDA: no, EMA: no, PMDA: no
Description: Installation of IV-PCA of methadone. Program to be used with no background infusion, boluses of 1 mg, and the intervals between boluses of 8 minutes.
Study: NCT04473989
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly subcutaneous administration of 40 ug
Study: NCT04621981
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group was treated with normal saline.
Study: NCT05361369
Drug: EVEGYN 600 mg/1000 mg/100 mg Vaginal Ovule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of 600 mg fenticonazole nitrate + 1000 mg tinidazole + 100 mg lidocaine
Study: NCT05384249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Study: NCT05367440
Drug: AZD5305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an oral dose of AZD5305 once daily
Study: NCT06077864
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once weekly subcutaneous injection
Study: NCT06775379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
Study: NCT05878015
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg intravenous every 6 hours on day 1 and day 2. 1000mg intravenous every 8 hours on day 3 as needed.
Study: NCT05021328
Drug: SBRT 7Gy✖️5 QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBRT 7Gy✖️5 QD
Study: NCT06091475
Drug: Other
Normalized name: others
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of mineralocorticoid receptor antagonists and/or sodium glucose cotransporter 2 inhibitors
Study: NCT05613569
Drug: KLS-2031
Approvals — FDA: no, EMA: no, PMDA: no
Description: KLS-2031 administered by transforaminal epidural injection
Study: NCT06343636
Drug: VG-3927
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation
Study: NCT06343636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation
Study: NCT06343636
Drug: VG-3927
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Dose Level
Study: NCT04280523
Drug: ESR-specific PET scan
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung ESR Density by PET: Investigators will use 18F-FES as an estrogen receptor (ESR)-specific PET tracer to determine lung ESR density. 18F-FES will be prepared according to published methods. Briefly, all subjects will be evaluated by PET imaging, using standardized protocols. Blood will be obtained just before FES injection to measure the endogenous estrogen level \[estradiol (E2)\], to rule out pregnancy in female patients, and some reserved for future studies of mechanism. Approximately 6 mCi (222 MBq) of 18F-FES will be administered intravenously over 1\~2 minutes, with scanning initiated 1 hour after administration of the tracer. Emission scans will be performed of the chest. A multimodality computer platform (Syngo; Siemens) will be used for image review and manipulation.
Study: NCT05666518
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage at the discretion of the treating physician
Study: NCT06104306
Drug: B/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered without regard to food
Study: NCT05238675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05155137
Drug: Drug Capsule (Valsartan + Amlodipine + Rosuvastatin)
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill with 3 medications (Valsartan 80 mg + Amlodipine 5 mg + Rosuvastatin 10 mg)
Study: NCT05895643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly injections s.c with placebo (BD Posiflush)
Study: NCT06780254
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules
Study: NCT06217094
Drug: NP-101 (3 g)
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be assigned to take 3 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
Study: NCT06217094
Drug: NP-101 (4.8 g)
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be assigned to take 4.8 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
Study: NCT06217094
Drug: NP-101 (6 g)
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be assigned to take 6 g of NP-101 orally once daily for 28 days pre Y-90 treatment.
Study: NCT05342376
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The parturients will receive 02 ml normal saline as placebo, to be administered intravenously over 10 minutes after umbilical cord is clamped.
Study: NCT06401330
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06401330
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06761313
Drug: Triple combination formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals will be randomly divided em two groups,Group I is going to be treated with Triplenex (1 drop twice a day) and Grupo II with Brimonidine Tartarate (1 drop twice a day), Timolol Maleate (1 drop twice a day) and Bimatoprost (1 drop at night). At baseline visit a complete ophthalmolgical exam will be performed along with three questionnaires (Ocular Surface Disease Index, Glaucoma Treatment Compliance Assessment Tool and National Eye Institute Visual Function Questionnaire),retinography, visual field, optic nerve OCT in all patients. This procedure will be repeated at baseline and within 4, 8, 12 weeks.
Study: NCT05179252
Drug: Shen-Fu injection
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese patent medicine made by modern technology
Study: NCT05179252
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline, used for sham control
Study: NCT06010303
Drug: LBL-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBL-007 will be administered at a standard dose intravenously.
Study: NCT04647435
Drug: APSCTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: APSCTC + Toragesic® placebo + Tramal® placebo
Study: NCT04647435
Drug: Toragesic®
Approvals — FDA: no, EMA: no, PMDA: no
Description: APSCTC placebo + Toragesic® + Tramal® placebo
Study: NCT06783192
Drug: MK-8527
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8527 capsule taken by mouth
Study: NCT06783192
Drug: LNG/EE
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG/EE combination tablet taken by mouth.
Study: NCT06097468
Drug: NisinZ® P
Approvals — FDA: no, EMA: no, PMDA: no
Description: NisinZ® P is an ultrapure Nisin Z concentrate produced by fermentation using the bacterium Lactococcus lactis obtained from sauerkraut
Study: NCT06493760
Drug: SSGJ-707
Approvals — FDA: no, EMA: no, PMDA: no
Description: bispecific antibody
Study: NCT06493760
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT00002102
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06429059
Drug: Protandim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protandim is an oral tablet derived from five different plants: Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), Curcuma longa (turmeric) and Bacopa monniera.
Study: NCT06429059
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin is a hormone that has long been known to play a role in regulating sleep. Melatonin supplements are commonly used to treat insomnia, but in recent years, melatonin has been found to play a wider role in human physiology including the potential regulation of autophagy.
Study: NCT06786338
Drug: SGB-9768
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGB-9768 for subcutaneous (SC) injection
Study: NCT06483802
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT05075408
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 2 SC injections of 30 mg placebo-matched to nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
Study: NCT05997602
Drug: FCN-159
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg/m² (Maximum dose does not exceed 8mg, the recommended oral dose for adults), orally, once daily, continuously for 28 days per cycle.
Study: NCT05829551
Drug: RAY1216 dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAY1216 dose 1 or Placebo
Study: NCT05829551
Drug: RAY1216 dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAY1216 dose 2 or Placebo
Study: NCT05829551
Drug: RAY1216 dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAY1216 dose 3 or Placebo
Study: NCT05829551
Drug: RAY1216 dose 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAY1216 dose 5 or Placebo
Study: NCT05829551
Drug: RAY1216 dose 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAY1216 dose 6 or Placebo
Study: NCT05829551
Drug: RAY1216 dose 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAY1216 dose 7 or Placebo
Study: NCT05829551
Drug: RAY1216 dose 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAY1216 dose 8 or Placebo
Study: NCT05829551
Drug: RAY1216 dose 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAY1216 dose 9 or Placebo with high fat meal
Study: NCT05829551
Drug: RAY1216 dose 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAY1216 dose 10 or Placebo with high fat meal